Previous close | 9.02 |
Open | 8.99 |
Bid | 9.11 x 400 |
Ask | 9.21 x 100 |
Day's range | 8.69 - 9.30 |
52-week range | 4.91 - 16.65 |
Volume | |
Avg. volume | 568,529 |
Market cap | 617.588M |
Beta (5Y monthly) | 1.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer Presented updat
SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2024 (the “Grant Date”), ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024. These inducement grants were granted
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC